Inhibitors in young boys with haemophilia
- PMID: 11030045
- DOI: 10.1053/beha.2000.0088
Inhibitors in young boys with haemophilia
Abstract
The development of an inhibitor antibody to factor VIII (or factor IX) in a child with haemophilia presents a major challenge to the paediatric haematologist. This article provides an overview of the incidence of inhibitor development in early childhood (30-52% in boys with severe haemophilia A), genetic risk factors, detection, high titre, low titre and transient inhibitors, and management. Treatment of patients with inhibitors is time-consuming and expensive. One should make every attempt to ensure that the boy's family has an understanding of inhibitors, treatment options, and just what is being recommended for their child and what this involves. Immune tolerance induction is successful in approximately 85% of boys with factor VIII inhibitors, but in only 40-50% of those with factor IX inhibitors. For treatment of bleeding episodes in children with high-titre (> or = 5 Bethesda Units) inhibitors, therapeutic options include activated prothrombin complex concentrates (APCC), rF VIIa, and (for factor VIII inhibitors) porcine factor VIII. The advantages and disadvantages of each are discussed. Although factor IX inhibitors are far less common (occurring in 2-3% of boys with haemophilia B), approximately 50% are accompanied by the occurrence of anaphylaxis or severe allergic reactions to any factor IX-containing product.
Similar articles
-
Inhibitor antibodies to factor VIII and factor IX: management.Semin Thromb Hemost. 2000;26(2):179-88. doi: 10.1055/s-2000-9821. Semin Thromb Hemost. 2000. PMID: 10919411 Review.
-
The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.Br J Haematol. 2006 Jun;133(6):591-605. doi: 10.1111/j.1365-2141.2006.06087.x. Br J Haematol. 2006. PMID: 16704433 Review.
-
Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia.Br J Haematol. 2004 May;125(3):366-8. doi: 10.1111/j.1365-2141.2004.04916.x. Br J Haematol. 2004. PMID: 15086418
-
Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.Thromb Haemost. 1999 Aug;82(2):531-9. Thromb Haemost. 1999. PMID: 10605747 Review. No abstract available.
-
Development of anaphylactic shock in haemophilia B patients with inhibitors.Blood Coagul Fibrinolysis. 1998 Mar;9 Suppl 1:S125-8. Blood Coagul Fibrinolysis. 1998. PMID: 9819043 Clinical Trial.
Cited by
-
Recurrent intramural hematoma of the small intestine in a severe hemophilia A patient with a high titer of factor VIII inhibitor: a case report and review of the literature.Int J Hematol. 2006 Aug;84(2):166-9. doi: 10.1532/IJH97.06053. Int J Hematol. 2006. PMID: 16926140
-
High rate of spontaneous inhibitor clearance during the long term observation study of a single cohort of 524 haemophilia A patients not undergoing immunotolerance.J Hematol Oncol. 2013 Aug 30;6:63. doi: 10.1186/1756-8722-6-63. J Hematol Oncol. 2013. PMID: 24001010 Free PMC article. Clinical Trial.
-
Sequential therapy with activated prothrombin complex concentrates and recombinant activated factor VII to treat unresponsive bleeding in patients with hemophilia and inhibitors: a single center experience.Blood Res. 2013 Dec;48(4):282-6. doi: 10.5045/br.2013.48.4.282. Epub 2013 Dec 24. Blood Res. 2013. PMID: 24466553 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical